Emirates Pharmaceuticals announces a voluntary precautionary withdrawal of specific batches of Nestlé infant formula (S26 AR GOLD)

The Emirates Pharmaceutical Corporation revealed the presence of an additional product S26 AR Within the scope of the voluntary and precautionary withdrawal of Nestlé infant formula products used under medical supervision only, and in order to preserve health and safety, the Corporation announced the operations affected by the withdrawal decision, which are: 5185080661,5271080661, 5125080661

This measure comes as a result of one of the production inputs containing traces of bacteria Bacillus cereuswhich may produce a substance Cereulidewhich may lead to health disorders, including food poisoning and some digestive symptoms such as nausea, vomiting, and abdominal pain.

The Corporation confirmed that, in coordination with Nestlé, all concerned batches available in distributors’ warehouses have been seized, while continuing to complete the procedures for withdrawing any remaining quantities from the markets, in accordance with the approved regulatory frameworks and in cooperation with the competent regulatory authorities in the country, to ensure the removal of the affected batches from all sales outlets, including electronic stores..

The Emirates Medicines Corporation explained, based on its keenness to enhance communication with consumers and ensure that they obtain information from reliable sources, that Nestlé Middle East and North Africa published the detailed statement regarding the precautionary recall, as it pledged, in addition to providing technical mechanisms that enable consumers in the country to verify the affected products and request a refund or replacement easily..

That includes:

The Emirates Drug Corporation called on consumers to take advantage of these channels and adhere to the instructions provided, in order to ensure the highest levels of safety and protection of public health.

It is noteworthy that these measures fall within the strategy of the Emirates Pharmaceutical Corporation, which aims to consolidate the drug security system in the country and ensure the sustainability of the provision of medical products in accordance with the highest standards of quality and safety. This strategy embodies the organization’s readiness and ability to respond quickly to protect public health, through an integrated control system based on proactive risk analysis and continuous monitoring of pharmaceutical supply chains locally and globally..

The Foundation also affirms its commitment to transparency in communication and responsibility in decision-making, in addition to strengthening institutional coordination with various relevant partners, to ensure continuity of health care, and to preserve patient safety and drug quality as a top priority in all regulatory frameworks and policies.